List of adverse effects of nilotinib

From WikiProjectMed
Jump to navigation Jump to search


This is a list of adverse effects of the anti-cancer drug nilotinib, sorted by frequency of occurrence.[1][2][3][4][5][6]

Very common

Very common (>10% incidence) adverse effects include:

Common

Common (1–10% incidence) adverse effects include:

  • Constipation
  • Diarrhoea
  • Vomiting
  • Upper abdominal pain
  • Indigestion
  • Joint pain
  • Muscle spasms
  • Pain in extremities
  • Asthenia
  • Peripheral oedema
  • Folliculitis
  • Upper respiratory tract infection (including pharyngitis, nasopharyngitis, rhinitis)
  • Skin papilloma
  • Eosinophilia
  • Lymphopenia
  • Insomnia
  • Anxiety
  • Depression
  • Diabetes mellitus
  • Hypercholesterolaemia
  • Hyperlipidaemia
  • Hypertriglyceridaemia
  • Hyperglycaemia
  • Loss of appetite
  • Dizziness
  • Hypoaesthesia
  • Peripheral neuropathy
  • Eye pruritus
  • Conjunctivitis
  • Dry eye (including xerophthalmia)
  • Vertigo
  • Flushing
  • Hypertension
  • Angina pectoris
  • Arrhythmia (including atrioventricular block, tachycardia, atrial fibrillation, ventricular extrasystoles, bradycardia)
  • QT interval prolonged
  • Palpitations
  • Cough
  • Dyspnoea
  • Abdominal distension
  • Abdominal discomfort
  • Taste changes
  • Flatulence
  • Abnormal liver function
  • Bone pain
  • Back pain
  • Erythema
  • Hyperhidrosis
  • Contusion
  • Acne
  • Dermatitis (including allergic, exfoliative and acneiform)
  • Night sweats
  • Fever without an infectious cause
  • Chest pain (including non-cardiac chest pain)
  • Chest discomfort
  • Decreased haemoglobin
  • Increased blood amylase
  • Increased blood alkaline phosphatase
  • Gamma-glutamyltransferase increased
  • Weight increased
  • Increased blood insulin
  • Increased lipoprotein (including very low density and high density)

Uncommon

Uncommon (0.1–1% incidence) adverse effects include:

References

  1. "Complete Nilotinib information from Drugs.com". Drugs.com. Archived from the original on 1 February 2014. Retrieved 25 January 2014.
  2. "Tasigna : EPAR - Product Information" (PDF). European Medicines Agency. Novartis Europharm Ltd. 18 October 2013. Archived (PDF) from the original on 4 February 2014. Retrieved 25 January 2014.
  3. "Tasigna 150mg Hard Capsules - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Novartis Pharmaceuticals UK Ltd. 9 September 2013. Archived from the original on 1 February 2014. Retrieved 25 January 2014.
  4. "TASIGNA® nilotinib" (PDF). TGA eBusiness Services. 21 October 2013. Archived from the original on 6 April 2017. Retrieved 25 January 2014.
  5. "Tasigna (nilotinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 17 July 2021. Retrieved 25 January 2014.
  6. Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
  7. 7.0 7.1 Chan, J; Shah, P; Moguel-Cobos, G (2019). "Nilotinib-Induced Dystonia and Cognitive Deficits in a Neurologically Normal Patient with Chronic Myeloid Leukemia". Case Reports in Neurological Medicine. 2019: 3679319. doi:10.1155/2019/3679319. PMC 6875312. PMID 31781436.
  8. Donatelli, C., D. Chongnarungsin, and R. Ashton. (Oct 2014). "Acute respiratory failure from nilotinib-associated diffuse alveolar hemorrhage". Leuk Lymphoma. 55 (10): 2408–9. doi:10.3109/10428194.2014.887714. PMID 24467220. S2CID 43118790.{{cite journal}}: CS1 maint: multiple names: authors list (link)